APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

(2014) B. Tessoulin et al.   BLOOD

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

(2014) Patricia A.J. Muller et al.   CANCER CELL

Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities

(2014) Bo Hong et al.   CURRENT DRUG TARGETS

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines

(2014) Patricia Izetti et al.   INVESTIGATIONAL NEW DRUGS

Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo

(2014) C R R Rocha et al.   Cell Death & Disease

P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives

(2013) Ziyad Binkhathlan et al.   CURRENT CANCER DRUG TARGETS

PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa

(2013) Manujendra N. Saha et al.   MOLECULAR CANCER THERAPEUTICS

Role of Glutathione in Cancer Progression and Chemoresistance

(2013) Nicola Traverso et al.   Oxidative Medicine and Cellular Longevity

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

(2013) X Peng et al.   Cell Death & Disease

Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies

(2012) S. Murray et al.   CANCER TREATMENT REVIEWS

P53 and its molecular basis to chemoresistance in breast cancer

(2012) Stian Knappskog et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

PRIMA-1Met/APR-246 induces wild-type p53-dependent suppression of malignant melanoma tumor growth in 3D culture and in vivo

(2011) Wenjie Bao et al.   CELL CYCLE

Quaternary structure of the specific p53–DNA complex reveals the mechanism of p53 mutant dominance

(2011) Ricardo Aramayo et al.   NUCLEIC ACIDS RESEARCH

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

(2010) Yves Pommier et al.   CHEMISTRY & BIOLOGY

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

(2010) Ahmed Ashour Ahmed et al.   JOURNAL OF PATHOLOGY

Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding

(2010) Joel L. Kaar et al.   PROTEIN SCIENCE

PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

(2009) Jeremy M.R. Lambert et al.   CANCER CELL

Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis

(2009) J M R Lambert et al.   ONCOGENE

Clinical Outcomes and Correlates of TP53 Mutations and Cancer

(2009) A. I. Robles et al.   Cold Spring Harbor Perspectives in Biology

PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2

(2008) J Shen et al.   ONCOGENE